Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Anemia Correction and Fibroblast Growth Factor 23 Levels in Left Ventricular Hypertrophy, and Early Endothelial Dysfunction in Chronic Kidney Disease, and Renal Transplant Patient

NCT03193073 is registered in ClinicalTrials.gov with Omnia Mohammed Hashem as lead sponsor.

NCT NCT03193073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03193073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Anemia Correction and Fibroblast Growth Factor 23 Levels in Left Ventricular Hypertrophy, and Early Endothelial Dysfunction in Chronic Kidney Disease, and Renal Transplant Patient
Lead sponsor
Omnia Mohammed Hashem
Phase
Not applicable
Overall status
Suspended
Start date
September 1, 2018
Completion date
December 1, 2020
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease, endothelial dysfunction, fibroblast growth factor 23, left ventricular hypertrophy